TABLE 5

Summary of the accuracy of DDI predictions using different rifampicin models (A–G)

ObservedModel AModel BModel CModel DModel EModel FModel G
Indmax 8,aIndmax 8 liver, 16 gut,Indmax 16Indmax 22.7Indmax 29.9Indmax 12Indmax 20
IndC50 0.32aIndC50 0.32IndC50 0.32IndC50 0.30IndC50 0.71IndC50 0.32IndC50 0.32
Rifampicin, i.v. MDZ
 Geometric mean fold induction1.991.711.722.042.132.111.962.15
 GMFE1.211.211.161.181.181.161.20
 RMSE0.510.470.360.380.380.380.40
 % Within acceptance limitsb83.310010083.383.310083.3
Rifampicin, oral MDZ
 Geometric mean fold induction18.16.479.6917.129.326.610.923.7
 GMFE3.262.211.701.961.851.991.75
 RMSE27.024.821.621.520.724.120.6
 % Within acceptance limitsb27.345.572.736.436.463.663.6
Rifampicin, all MDZ (i.v. and oral)
 Geometric mean fold inductionn/a
 GMFE2.301.791.481.641.581.651.53
 RMSE21.720.017.417.316.719.416.5
 % Within acceptance limitsb47.158.882.452.952.976.570.6
Rifampicin, all victims (i.v.)
 Geometric mean fold inductionn/a
 GMFE1.241.241.151.161.131.161.17
 RMSE0.530.560.350.360.350.420.37
 % Within acceptance limitsb90.010010090.090.010090.0
Rifampicin, all victims (oral)
 Geometric mean fold inductionn/a
 GMFE2.812.121.691.911.801.961.72
 RMSE21.519.917.720.519.219.118.9
 % Within acceptance limitsb26.326.368.452.652.673.768.4
Rifampicin, all victim drugs
 Geometric mean fold inductionn/a
 GMFE2.121.771.481.611.531.631.51
 RMSE17.416.114.416.515.515.515.3
 % Within acceptance limitsb48.351.779.365.565.579.375.9
  • GMFE, geometric mean fold error; n/a, not applicable; RMSE, root mean square error.

  • a Default rifampicin induction parameters (V12). Geometric mean fold induction for observed data were calculated in a meta-analysis using published methodology (Einolf, 2007; Cubitt et al., 2011; Ghobadi et al., 2011; Barter et al., 2013; Supplemental Table 3).

  • b Acceptance limits proposed by Guest et al. (2011).